HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya

• Published in: Journal of viral hepatitis 2011-10, Vol.18 (10), p.e447-e452
• Main Authors: Kim, H. N., Scott, J., Cent, A., Cook, L., Morrow, R. A., Richardson, B., Tapia, K., Jerome, K. R., Lule, G., John-Stewart, G., Chung, M. H.
• Format: Article
• Language: English
• Subjects: Adult; Anti-HIV Agents - administration & dosage; Antiretroviral Therapy, Highly Active - methods; DNA, Viral - blood; Drug Resistance, Viral; Female; Hepatitis B - complications; Hepatitis B - drug therapy; Hepatitis B - virology; Hepatitis B Antibodies - blood; Hepatitis B Surface Antigens - blood; Hepatitis B virus; Hepatitis B virus - drug effects; Hepatitis B virus - isolation & purification; HIV Infections - complications; HIV Infections - drug therapy; HIV-1; Human immunodeficiency virus; Humans; Kenya; Lamivudine - administration & dosage; lamivudine resistance; Male; Nevirapine - administration & dosage; Stavudine - administration & dosage; Treatment Outcome; Viral Load
• ISSN: 1352-0504; 1365-2893
• DOI: 10.1111/j.1365-2893.2011.01466.x

Widespread use of lamivudine in antiretroviral therapy may lead to hepatitis B virus resistance in HIV–HBV coinfected patients from endemic settings where tenofovir is not readily available. We evaluated 389 Kenyan HIV‐infected adults before and for 18 months after starting highly active antiretroviral therapy with stavudine, lamivudine and nevirapine. Twenty‐seven (6.9%) were HBsAg positive and anti‐HBs negative, 24 were HBeAg negative, and 18 had HBV DNA levels ≤10 000 IU/mL. Sustained HBV suppression to